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Abstract
The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of
angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer,
which may have some impacts in the current clinic practice.
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The recent FDA approval of ramucirumab (a fully human
IgG1 monoclonal antibody against the vascular endothe-
lial growth factor receptor [VEGFR]-2 extracellular do-
main), in combination with FOLFIRI (RAISE trial) [1], has
added a third agent to our armamentarium of angiogen-
esis inhibitors (bevacizumab and ziv-aflibercept) in the
second-line treatment of metastatic colorectal cancer
(mCRC). This has also resulted in further crowding of the
existing treatment landscape, especially in the current sce-
nario where these anti-VEGF agents are characterized by
comparable efficacy and similar toxicity profiles.
Angiogenesis plays a crucial role in colorectal tumori-
genesis, and the VEGF pathway is the only target that
has been validated to date [2]. The VEGF family of li-
gands consists of a number of glycoproteins including
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental
growth factor (PlGF). They bind to their cognate recep-
tors VEGFR-1, VEGFR-2, and VEGFR-3 leading to intra-
cellular signaling with resultant endothelial proliferation
and migration. Before the approval of ramucirumab, sev-
eral targeted agents aimed at inhibiting VEGF signaling
have been developed for the treatment of mCRC, includ-
ing antibody-mediated inhibition of ligand binding to
the target VEGF receptors (bevacizumab; IgG1 Fc-VEGF
receptor construct, ziv-aflibercept) and inhibitor of
intracellular receptor tyrosine kinases of VEGFRs (rego-
rafenib) [3, 4]. A series of phase III clinical trials have
confirmed the efficacy of these VEGF inhibition strat-
egies in the treatment of mCRC. Consequently, the use
of anti-angiogenic treatments in conjunction with
chemotherapy has become an accepted standard of care
in mCRC.
ML18147 (a study of Avastin [bevacizumab] plus
crossover fluoropyrimidine-based chemotherapy in pa-
tients with metastatic colorectal cancer) was the first
study to demonstrate the benefit of continuing anti-
angiogenic agent bevacizumab (in combination with
chemotherapy) as a second-line therapy, even after pre-
vious exposure to the agent [5]. The VELOUR trial
(aflibercept versus placebo in combination with irinotecan
and 5-FU in the treatment of patients with metastatic
colorectal cancer after failure of an oxaliplatin-based regi-
men) established the efficacy of ziv-aflibercept and FOL-
FIRI combination in mCRC patients who had progressed
on oxaliplatin-containing chemotherapy [6]. The recent
phase III RAISE study (ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with
metastatic colorectal carcinoma that progressed during or
after first-line therapy with bevacizumab, oxaliplatin, and
a fluoropyrimidine) demonstrated that ramucirumab in
combination with FOLFIRI significantly prolonged overall
survival (OS; 13.3 vs. 11.7 months, hazard ratio [HR] =
0.84, 95 % confidence interval [CI] 0.73–0.98, P = 0.0219)
and progression-free survival (PFS; 5.7 vs. 4.5 months,
HR = 0.79, 95 % CI 0.70–0.90, P < 0.0005) in patients with
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mCRC whose disease had progressed during or after first-
line treatment with bevacizumab, oxaliplatin, and a fluoro-
pyrimidine [1].
A careful review of results indicates noteworthy simi-
larities between these three studies. All of these trials
demonstrated a benefit of combining an anti-VEGF
agent (bevacizumab, ziv-aflibercept, or ramucirumab)
with chemotherapy beyond initial progression in pa-
tients with mCRC. Although cross-trial comparison
suffers from inherent limitations and should be inter-
preted with caution, it is interesting to note that the
three anti-VEGF agents evaluated in these trials exhib-
ited a similar improvement in OS (TML 1.4 months,
VELOUR 1.4 months, RAISE 1.6 months) and PFS
(TML 1.7 months, VELOUR 2.2 months, RAISE
1.2 months). The stratified HR for OS were also quite
similar in the TML (0.83), VELOUR (0.82), and RAISE
(0.84) trials. Moreover, the toxicity profiles of these
agents overlapped, with a higher incidence of anti-
VEGF-associated adverse events (such as hemorrhage,
hypertension, and proteinuria) in the anti-angiogenesis
agent arms, as was expected.
There were, however, a few important dissimilarities
noted as well, which were primarily related to the treat-
ment regimens used in these studies. In the VELOUR and
RAISE trials, all patients received oxaliplatin- and
fluoropyrimidine-based regimens as first-line treatment.
In the ML18147 study, approximately 60 % of patients re-
ceived irinotecan-based, and the remaining 40 % received
oxaliplatin-based regimen as the first-line therapy. All pa-
tients in the ML18147 and RAISE trials had received pre-
vious treatment with bevacizumab, as compared with only
30 % of patients in the VELOUR trial. The anti-VEGF
agents used in these trials also differ with respect to their
mechanism of action and pharmacokinetic properties. For
example, bevacizumab targets VEGF-A to cause ligand se-
questering; ziv-aflibercept blocks VEGF-A, VEGF-B, and
PlGF using the IgG1 Fc-VEGF receptor construct; and
ramucirumab targets VEGFR-2 to prevent receptor activa-
tion by VEGF-A. Despite these differences, data from
these three trials provide confirmatory evidence that in-
hibition of tumor angiogenesis beyond initial disease pro-
gression is an effective treatment strategy in mCRC.
However, questions remain: potential predictive markers
for these VEGF-A/VEGFR-2 pathway inhibitors, whether
colorectal cancer may develop crossover tolerability/re-
sistance to these treat different agents, potential oppor-
tunities to the possible mechanisms of moderate benefits
(~1.4 months survival advantage) of these anti-angiogenic
agents in mCRC, and possibilities of these anti-angiogenic
agents in combination with other biologic target oriented
agents, in particular immune checkpoint inhibitors.
The efficacy of bevacizumab and aflibercept may be af-
fected by the local concentration of targeted ligand(s).
Expression of VEGF-A and other ligands may increase
after the loop blockage as a physiological response to
rebalance the pathway, e.g., aflibercept benefits less in
those patients previously exposed to bevacizumab (Vel-
our data). Biologic efficacy of ramucirumab may be less
influenced by the local concentration of VEGF-A be-
cause of binding in the VEGFR-2 extracellular domain.
A limited benefit of this class of anti-angiogenic agents
may be partly due to the fact that no selection criteria
have been used to enrich for those patients who may be
likely to derive a durable benefit from treatment. Based
on the heterogeneous nature of colorectal cancer, to
identify predictive biomarkers for VEGF signaling in-
hibitors may potentially broaden the clinical impact of
these agents and might even distinguish the clinic ap-
plication of each agent. Many biomarker studies have
been developed and others are ongoing; however, there
has been no prospective validation reported. For ex-
ample, low VEGF(165)b:VEGF(total) ratio may be a
predictive marker for bevacizumab in metastatic colo-
rectal cancer [7], and individuals with high relative
levels may not benefit from bevacizumab; low serum
angiopoietin-2 (Ang-2), an inhibitory ligand of endo-
thelial Tie-2 receptor, may be a predictive marker; and
low serum neuropilin-1 (NRP-1) may predict better re-
sponse and overall outcome of tivozanib, an oral VEGF
TKI, or bevacizumab in combination with mFOLFOX6
[8]. A meta-analysis of individual patient data from six
randomized phase III trials to explore the potential re-
lationships between 195 common genetic variants in
the vascular endothelial growth factor (VEGF) pathway
and bevacizumab treatment outcome suggests that vari-
ants in VEGF-A, EPAS1, IL8RA, VHL, and VEGFC
have potential value in predicting bevacizumab treat-
ment outcome [9].
So far, no selection criteria have been used to en-
rich for patients that might be more likely to derive
durable responses from a particular anti-VEGF ther-
apy. Consequently, optimal utilization of the available
anti-angiogenesis options remains an unfulfilled goal
at this time. In current clinical practice, decisions re-
garding the choice of agent are usually guided by
physicians’ familiarity with the drug and the cost of
therapy. Identification of robust clinical and molecular
biomarkers to predict sensitivity, resistance, or toxicity
from VEGF signaling inhibitors would be considered a
significant breakthrough, as it might help distinguish
the clinical application of each agent [10]. Translational
research efforts targeted towards this goal are actively
ongoing. Other clinically relevant questions that cur-
rently remain unanswered include identification of op-
timal sequencing strategy and the cost-to-benefit ratio
of these anti-VEGF therapies in the management of
mCRC.
Goel and Sun Journal of Hematology & Oncology  (2015) 8:92 Page 2 of 3
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GG drafted the manuscript and revised it critically for important intellectual
content. WS revised the manuscript critically for important intellectual
content. Both authors read and approved the final manuscript.
Acknowledgements
Thanks for the invitation from the JHO board.
Received: 24 June 2015 Accepted: 2 July 2015
References
1. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero
R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI
in patients with metastatic colorectal carcinoma that progressed during or
after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol.
2015;16:499–508.
2. Ferrara N. Vascular endothelial growth factor as a target for anticancer
therapy. Oncologist. 2004;9 Suppl 1:2–10.
3. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity.
Nat Rev Cancer. 2008;8:579–91.
4. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of
the role of Fc gamma receptor polymorphisms in the response to
monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.
5. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al.
Continuation of bevacizumab after first progression in metastatic colorectal
cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
6. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et
al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan
improves survival in a phase III randomized trial in patients with metastatic
colorectal cancer previously treated with an oxaliplatin-based regimen. J
Clin Oncol. 2012;30:3499–506.
7. Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O’Dwyer PJ, et al.
Association between VEGF splice isoforms and progression-free survival in
metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer
Res. 2012;18(22):6384–91.
8. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky
TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical
outcome of colorectal cancer patients treated with bevacizumab-containing
therapy. Br J Cancer. 2010;103:1407–14.
9. de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, et al. Genetic
variability of VEGF pathway genes in six randomized phase III trials assessing
the addition of bevacizumab to standard therapy. Angiogenesis.
2014;17:909–20.
10. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug
development in oncology. J Hematol Oncol. 2014;7:70.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Goel and Sun Journal of Hematology & Oncology  (2015) 8:92 Page 3 of 3
